Genzyme Opts Into Alnylam's ALN-AT3 Hemophilia Program - Quick Facts

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) and Genzyme, a Sanofi company (SNY) announced that Genzyme has elected to opt into Alnylam's investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.

ALN-AT3 is the third Alnylam product for which Genzyme has exercised its opt-in right since the formation of the companies' global alliance in January 2014, the first two occurring at the close of the deal in early 2014 for patisiran and revusiran, investigational RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis.

In the case of ALN-AT3, Genzyme has elected presently to opt into the program for its ROW rights. For regional programs where Genzyme will develop and commercialize in their ROW territory, such as ALN-AT3 as currently structured, Genzyme pays 20% of global development costs. Alnylam is eligible to receive milestones totaling up to $75 million per product for regional and co-develop/co-promote programs.

Genzyme's opt-in decision was based on encouraging clinical data from the Phase 1 trial of ALN-AT3, including positive interim data. "ALN-AT3 represents a unique and promising new approach for the potential treatment of hemophilia," said David Meeker, CEO of Genzyme.